Genmab reported a 22% rise in sales for the first nine months of 2026.

Nov 5, 2026, 1:42 PM ETResultsRead the original at globenewswire.com

Good for GMAB

Genmab's sales grew, led by higher royalties, and it reported a profit. Its 2026 forecast stayed unchanged and pipeline spending increased, but the reported growth supports a favorable outlook.

GMAB · Genmab A/S

AI read · Good for GMAB

The AI's read

Higher sales of DARZALEX and Kesimpta lifted royalty income, and EPKINLY/TEPKINLY also brought in sales. Genmab increased spending on its product pipeline and kept its 2026 forecast unchanged. Still, growing sales and reported profits support a positive read.

Get alerts for GMAB

Follow Genmab A/S (GMAB) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for GMAB

Free on the App Store and Google Play, or on the web.